How MISLEADING MISGUIDING WALL STREET JOURNAL HEADLINE IS .
Read below.
Mayne Pharma expects 1H FY25 revenues to be $210 – $215 million, reflecting 12 – 14% growth on 1H FY24. In addition, Mayne Pharma expects to report 1H FY25 underlying EBITDA1 of $30 – $32 million representing growth of 275 – 300% on 1H FY24.
So this growth in first half in revenue is low. WOW.
Shawn Patrick O’Brien, CEO and Managing Director, Mayne Pharma said. “We have experienced solid trading conditions in the first half as we execute against our corporate strategies, with robust revenue growth recorded particularly within our Women’s Health segment. We look forward to further updating our investors on our progress and plans at the half year results presentation in late February.”
So as i have written before,MYX management is already promosing to give further updates on 27/2/25.
MYX Price at posting:
$5.52 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)